287916-51-2

Downstream Products

• 31848-80-3 1L-N,N'-dibenzylidene-O⁴-(N,O⁴-(Ξ)-benzylidene-4-methyl-3-methylamino-β-L-3-deoxy-arabinopyranosyl)-O⁶-((6Ξ)-2,6-bis-benzylideneamino-α-D-erythro-2,3,4,6,7-pentadeoxy-heptopyranosyl)-2-deoxy-streptamine 
• 35639-31-7 1D-O⁴-[(6Ξ)-2,6-bis-(4-nitro-benzylideneamino)-α-D-erythro-2,3,4,6,7-pentadeoxy-heptopyranosyl]-O⁶-[4-methyl-3-methylamino-N,O⁴-((Ξ)-4-nitro-benzylidene)-β-L-3-deoxy-arabinopyranosyl]-N,N'-bis-(4-nitro-benzylidene)-2-deoxy-streptamine 
• 35683-90-0 1D-O⁴-[(6Ξ)-2,6-bis-(2,6-dichloro-benzylideneamino)-α-D-erythro-2,3,4,6,7-pentadeoxy-heptopyranosyl]-N,N'-bis-(2,6-dichloro-benzylidene)-O⁶-[N,O⁴-((Ξ)-2,6-dichloro-benzylidene)-4-methyl-3-methylamino-β-L-3-deoxy-arabinopyranosyl]-2-deoxy-streptamine 
• 31962-11-5 1D-O⁴-[(6Ξ)-2,6-bis-(4-chloro-benzylideneamino)-α-D-erythro-2,3,4,6,7-pentadeoxy-heptopyranosyl]-N,N'-bis-(4-chloro-benzylidene)-O⁶-[N,O⁴-((Ξ)-4-chloro-benzylidene)-4-methyl-3-methylamino-β-L-3-deoxy-arabinopyranosyl]-2-deoxy-streptamine 
• 31848-85-8 1D-O⁴-[(6Ξ)-2,6-bis-(2,3,4,5,6-pentafluoro-benzylideneamino)-α-D-erythro-2,3,4,6,7-pentadeoxy-heptopyranosyl]-O⁶-[4-methyl-3-methylamino-N,O⁴-((Ξ)-2,3,4,5,6-pentafluoro-benzylidene)-β-L-3-deoxy-arabinopyranosyl]-N,N'-bis-(2,3,4,5,6-pentafluoro-benzylidene)-2-deoxy-streptamine 
• 31848-84-7 1D-O⁴-((6Ξ)-2,6-bis-dodecylideneamino-α-D-erythro-2,3,4,6,7-pentadeoxy-heptopyranosyl)-O⁶-(N,O⁴-(Ξ)-dodecane-1,1-diyl-4-methyl-3-methylamino-β-L-3-deoxy-arabinopyranosyl)-N,N'-didodecylidene-2-deoxy-streptamine 

Relevant academic research and scientific papers

Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives

Protein targets for disease intervention through inhibition of nucleic acid metabolism are disclosed. Novel polypeptides for one such target, DNA-dependent ATPase A, and novel polynucleotides encoding DNA-dependent ATPase A are disclosed. Phosphoaminoglycoside compounds which act on such protein targets to inhibit nucleic acid metabolism. In addition, screening assays for identifying compounds that inhibit nucleic acid-dependent ATPase activity, including, but not limited to, DNA-dependent ATPase A, are disclosed. Such compounds are useful in the treatment of diseases, including but not limited to cancer and infectious disease, through disruption of nucleic acid metabolism and induction of apoptosis. Moreover, methods for prevention and treatment of diseases including, but not limited to cancer and infectious disease are disclosed.

1-Nitro-aminoglycoside derivatives, pharmaceutical compositions containing them and such derivatives for use as pharmaceuticals

Hydroxymethylated aminoglycoside derivatives which are useful, in particular as anti-bacterially active antibiotics.

1-Desamino-1-hydroxy and 1-desamino-1-epi-hydroxy-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols; 1-desamino-1-oxo-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols, intermediates and use as antibacterial agents

This invention relates to the preparation of novel 1-desamino-1-oxo-aminoglycosides and their use as intermediates in the preparation of novel 1-desamino-1-hydroxy and 1-desamino-1-epi-hydroxyaminoglycoside antibacterial agents.

Selective acylation of the C-1 amino group of aminoglycoside antibiotics

A novel process for preparing novel 1-N-acyl-4,6-di-(aminoglycosyl)aminocyclitols is disclosed. The compounds are useful as antibacterial agents.